These vaccine mandates are already in place to attend school in the US

valentinrussanov/iStock

(NEW YORK) — By early next year, all eligible students attending a Los Angeles public school will be required to be fully vaccinated against COVID-19.

The school district is the largest in the country to mandate the shot — which joins a list of other vaccines already required to attend school that protect against highly contagious diseases.

All 50 states and the District of Columbia have vaccine requirements for children to attend school and child care facilities, including laws around allowable exemptions.

Massachusetts became the first state to enact a school vaccination requirement in the 1850s for the smallpox vaccine — the first immunization developed against a contagious disease — according to a publication by the U.S. Centers for Disease Control and Prevention. Other states followed suit, and by the 1980-1981 school year, all states had vaccination requirements for students entering the classroom, the CDC said.

Children in close proximity with poor ventilation and hygiene practices can lead to “transmission events,” said Dr. John Brownstein, an epidemiologist at Boston Children’s Hospital and an ABC News contributor.

“This is why vaccine mandates in schools have been super important,” Brownstein said. “They create a safe environment where you can recognize that you will not have transmission of a wide range of infectious diseases like measles, mumps, rubella, whooping cough.”

The mandates have been “very successful” in preventing outbreaks of vaccine-preventable diseases, he said.

Thanks to vaccination efforts, many highly contagious diseases that were once common, such as measles, mumps, whooping cough (aka pertussis) and chickenpox, are now rare, while polio and smallpox have been eradicated in the U.S. Routine child vaccination is estimated to prevent 936,000 premature deaths and 419 million illnesses in American children born between 1994 and 2018, according to the CDC.

Vaccine mandates for child care and schools vary by state. All require vaccines that protect against polio, diphtheria, tetanus, whooping cough, measles and rubella, according to the Immunization Action Coalition (IAC), a vaccine education and advocacy organization. Nearly all states require vaccines that protect against mumps, chickenpox, hepatitis B and pneumococcal disease.

Vaccines that aren’t widely required by states include ones for the flu, hepatitis A, rotavirus and HPV, according to IAC. The U.S. stopped routine vaccination for smallpox — which has been eradicated globally — in the 1970s.

“Precedents have been set that you can protect your community by requiring school vaccination requirements,” L.J Tan, chief policy and partnerships officer for IAC, told ABC News.

For the 2019-2020 school year, about 95% of children in kindergarten in the U.S. had received the DTaP (diphtheria, tetanus and pertussis), MMR (measles, mumps and rubella) and varicella (chickenpox) vaccines, according to the CDC, with roughly 5% exempt from or not up to date on certain doses.

The agency has observed a decrease in vaccination rates during the pandemic, as COVID-19 has disrupted school and routine well visits for many families. There was a 14% drop in public sector vaccine ordering in 2020-2021 compared to 2019, and measles vaccine ordering decreased by over 20%, the CDC reported.

The decline in routine pediatric immunizations has been very concerning for public health experts.

“Whenever we have a decrease in coverage, that could be an opportunity for these infections to reemerge and cause outbreaks — and one of the most obvious, recent examples is measles,” Dr. Flor Munoz, a pediatric infectious disease specialist at Texas Children’s Hospital and Baylor College of Medicine in Houston, told ABC News.

In 2019, the U.S. saw its largest measles outbreak in 25 years, with 1,282 cases confirmed in 31 states, mostly among people not vaccinated against the virus, according to the CDC.

It’s especially important that children stay up-to-date on vaccines as many return to in-person learning and routine activities, Munoz said.

“All of these other diseases that are vaccine-preventable can reemerge at any time,” Munoz said. “Vaccination is the easiest way and the best way to prevent any of these potentially serious infections.”

Pediatric COVID-19 rates have reached record levels in the U.S. as students return to school. In the last two weeks, nearly half a million children have tested positive for COVID-19, according to the latest report on pediatric coronavirus cases from the American Academy of Pediatrics and the Children’s Hospital Association.

Pfizer’s COVID-19 vaccine is authorized for people as young as 12 and approved by the Food and Drug Administration for those ages 16 and up. The pharmaceutical company has said it plans to submit vaccine safety data on 5- to 11-year-olds to the FDA by the end of September.

Currently, no state requires the COVID-19 vaccine for children ages 12 and older for school entry, though some are mandating it for certain state employees and many colleges are requiring it for students.

The Los Angeles Unified School District’s Board of Education last week approved a mandate that students ages 12 and up be fully vaccinated against COVID-19 by Jan. 10, 2022, to attend class in-person. At this time, the school district said it is not requiring booster shots, which the Biden administration is planning to be made available as soon as next week for the general public at least eight months after their second dose.

Beyond Los Angeles, nearby Culver City is mandating that public school students get the vaccine this school year, and two San Francisco Bay Area districts are considering the same. More school districts may likely follow suit, creating a “domino effect,” Brownstein said, especially as younger children become eligible to get the vaccine.

“A safe vaccine that can prevent transmission, protect our kids and ensure that they can stay in in-person learning actually makes a lot of sense,” he said. “And there’s historical precedent for doing so.”

Copyright © 2021, ABC Audio. All rights reserved.

What to expect as FDA advisory panel debates Pfizer COVID booster shots

carmengabriela/iStock

(WASHINGTON) — The Food and Drug Administration’s independent advisory committee will convene in open session Friday to review the latest data submitted by Pfizer and discuss whether a booster dose is safe enough for widespread use and whether it’s necessary and effective at improving protection levels against COVID-19.

Their vote will be non-binding — the FDA is not required to follow the Vaccines and Related Biological Products Advisory Committee’s (VRBPAC) recommendations — but they generally do so.

After that vote, the FDA will decide whether they will formally amend their current vaccine approval for Pfizer. Next week the matter heads to the Centers for Disease Control and Prevention’s independent advisory panel (ACIP), where that panel will weigh on a more granular level who should get a booster and when? The CDC director will then formally sign off on whatever ACIP recommends.

Friday morning’s opening remarks are set to kick off at 8:30 a.m. ET, followed by introductions by the FDA, presentations from CDC representatives, a discussion about booster protection and a presentation from Pfizer executives who will make the case for why boosters are appropriate.

After a public hearing portion in the afternoon and a question-and-answer session on both Pfizer’s and the FDA’s presentations, the committee will debate the issue for roughly two hours. A vote is expected at about 4:45 p.m. ET, if they stay on schedule.

The meeting Friday comes amid a contentious debate on the timeline for boosters, with some health experts vehement that the data and timing is still premature.

Two top FDA officials who are leaving the agency later this year publicly waded into the debate on Monday, splitting from the agency and arguing in a scientific journal that it was too soon to give booster shots to the general public since the vaccines still offer strong protection against serious disease.

Both are scheduled to attend Friday’s discussion. One of them, the director of the agency’s office of vaccines research and review, is supposed to give an overarching introduction of the topic for the FDA in the beginning of the day.

Also joining Friday’s meeting is the head of Israel’s public health services, Dr. Sharon Alroy Preis, who is set to present data on booster protection against COVID infection and severe disease.

In a review of Pfizer’s data, also released Wednesday, the FDA appeared to be noncommittal on the necessity for boosters. The agency pointed out that Pfizer’s efficacy data could be hampered by the limitations of studying boosters in real-world situations, which can introduce complicating factors.

“There are many po­ten­tial­ly rel­e­vant stud­ies, but FDA has not in­de­pen­dent­ly re­viewed or ver­i­fied the un­der­ly­ing da­ta or their con­clu­sions,” the agency wrote in its briefing.

Naming no one — but nodding to those lingering concerns — Pfizer’s CEO Albert Bourla penned an open letter on Thursday making the case for booster shots.

“This week we are approaching another pivotal moment in our ongoing fight against the virus,” Bourla writes of Friday’s FDA advisory committee. “Since the start of this pandemic, Pfizer and BioNTech have pledged to follow the science and keep people informed about our progress to help bring an end to this global health crisis. We have stayed true to our commitment of full transparency without selectively cherry-picking data.”

Copyright © 2021, ABC Audio. All rights reserved.

Confused about boosters? Here are some answers

SolStock/iStock

(NEW YORK) — On Friday, an advisory panel for the Food and Drug Administration will weigh in on a debate that has been broiling since the Biden administration announced last month that the country would begin to roll out booster shots against COVID-19.

This panel, which is independent of the FDA and the Biden administration, will look at the data recently submitted by Pfizer on booster shots and make a recommendation. The FDA will then decide whether they will formally amend their current vaccine approval for Pfizer, and the Centers for Disease Control and Prevention, which has its own advisory committee, will review the information and make a decision.

But the back-and-forth leading up to this process, and the president’s involvement in an otherwise non-political decision, has left many Americans confused about who really needs boosters and when.

Do I need a booster shot, and if so, when?

Unfortunately, there’s no clear answer to this question yet. But it will come sometime in the next week, as the FDA and CDC’s advisory committees discuss the available data.

For now, the one thing to know is that the vast majority of vaccinated people are still well-protected by their vaccines.

“If you have a good immune system, I would certainly not go out and get a booster before anything is recommended. I feel strongly that we have to go by the scientific consensus, which really hasn’t been played out yet,” said Dr. Paul Goepfert, director of the Alabama Vaccine Research Clinic at the University of Alabama.

The latest CDC data found that over 90% of people hospitalized with COVID are still unvaccinated.

And while breakthrough infections happen, particularly as protection against mild infection wanes, the vaccines continue to protect Americans from ending up in the hospital with COVID, as well as vastly reducing their likelihood of death.

The only group that’s potentially at more risk of a serious breakthrough infection are older people who got their vaccines early on in the rollout. Recent studies by the CDC showed that protection against hospitalization for people over 65 has decreased to around 76-80%.

“At the end of the day, the purpose of the vaccines is to prevent hospitalizations and deaths, and they’re doing that very effectively still,” said Dr. Carlos Del Rio, executive associate dean of Emory University School of Medicine.

“Maybe a little less effective for people over the age of 60 or with comorbidities, but still, if you look around the hospitals, the people hospitalized today are people who haven’t received the vaccine.”

Additional vaccine doses, although not quite a booster, have already been approved by the CDC for the roughly 7 million immunocompromised Americans who didn’t have an optimal response to the first round of mRNA vaccines. Nearly 2 million Americans have gotten an additional shot since the FDA and CDC approved them in August for that subset of people.

The CDC officially recommended a third dose of an mRNA vaccine for immunocompromised Americans in August, allowing the approximately 7 million Americans who didn’t get an optimal immune response to their initial vaccine doses of Pfizer or Moderna to gain more protection.

There’s been a lot of debate as the process plays out. What’s the controversy?

When the Biden administration announced that it would roll out a booster shot program beginning Sept. 20, the White House’s COVID response team said it was to get ahead of the virus.

“You don’t want to find yourself behind, playing catch up,” Dr. Anthony Fauci, the nation’s top infectious disease expert, said when announcing the plan. “Better stay ahead of it than chasing after it.”

The White House has relied heavily on Israel’s progress. Data from the country, where the vaccine process began sooner than in the U.S., shows that vaccine protection against serious disease has now begun to wane.

But quickly, career scientists pushed back on the White House’s announcement, saying there wasn’t enough U.S. data to support boosters yet — all the current evidence shows vaccines still protect most Americans against serious disease.

For experts in that camp, the focus usually narrows in on the 80 million Americans who aren’t vaccinated at all. Increasing protection across more of the country would stamp out transmission.

“We’re spending way too much time talking about boosters when we need to be spending time talking about the people that haven’t been vaccinated,” said Del Rio.

But on the other hand, studies do show that general protection against mild infection is waning, even if it’s staying strong against hospitalization.

“We need to reinforce the armor,” said Dr. Todd Ellerin, an ABC News medical contributor and the director of infectious diseases at South Shore Health in Massachusetts.

Ellerin predicted a triple threat ahead: a surge of delta infections, higher transmission during the winter months and close to half the country remaining unvaccinated.

“I think there are strong arguments for both sides and we just have to see,” Ellerin said.

The FDA’s independent advisory committee meets all day on Friday, and plans to vote in the late afternoon. For now, they’re only meeting about Pfizer, the first vaccine to submit its data.

If the FDA panel votes to move forward with boosters, the CDC’s advisory committee will meet almost a week later to nail down the details: who gets boosters and how soon.

The FDA and CDC committees are looking at Pfizer booster shots. What’s the deal with boosters for people who got J&J or Moderna?

Both Johnson & Johnson and Moderna are expected to follow Pfizer and run their data by the official FDA and CDC channels in the coming weeks in an effort to get approval for booster shots.

But both companies maintain protection is still strong against severe infection.

Moderna, in an analysis of various studies released on Wednesday, even made the case that the company’s original vaccine appears to generate the strongest protection among the three currently authorized vaccines.

Nevertheless, Moderna President Stephen Hoge told ABC News in an interview on Wednesday that “protection is not permanent” and “we’re not going to be able to defy gravity forever.”

Newly published data from Moderna’s booster shot trial showed a lower risk of breakthrough infections among people vaccinated eight months ago compared to people vaccinated 13 months ago.

Unlike Pfizer, Moderna’s third booster will be a half-dose. They say their data shows that boosting with a half-shot seems to generate more than enough immune response.

For J&J, the one-shot series chosen by about 14 million Americans, a study found that the vaccine still provided a durable immune response at least eight months later, even without a booster dose.

Another study, not yet peer reviewed, found more good news: The J&J booster dose actually boosted antibody levels higher than they were after the initial shot.

And while it will be a few weeks before there’s more concrete news on the J&J booster shots, there’s room in the timeline. Most Americans didn’t receive the J&J vaccine until late spring of 2020, since it was approved after the mRNA vaccines. That means the J&J boosters won’t be widely necessary until November at the earliest — if the FDA and CDC decide they’re needed at all.

There is not enough data yet on mixing and matching vaccines, though the CDC is actively researching it.

And for all three of the vaccines, recipients have a common question: will I need to get a booster routinely? Experts, wary of predicting anything about the unpredictable global pandemic, said it’s possible, but unlikely.

“My prediction is that as long as the COVID rates are going down, we will not need a continuous boost,” Goepfert said. That could change, however, if a new viral strain requires a newly tailored vaccine.

Are booster shots safe?

Pfizer, the only vaccine so far to have its data reviewed by the FDA, found no safety concerns among the 300 trial participants who were part of its clinical trial. Pfizer followed the participants for up to three months after getting their third shot.

Peoples’ reactions to the booster shots were not significantly different from their reactions to a second dose, FDA and Pfizer both wrote in their separate briefing documents.

“No deaths, vaccine-related serious adverse events, or events of myocarditis, pericarditis, anaphylaxis, appendicitis, or Bell’s palsy were reported among study participants who received the … booster dose,” the FDA wrote in a review of Pfizer’s safety data.

Moderna and J&J have not yet had their data reviewed by the FDA, but have said they found no safety concerns in their clinical trials of booster shots.

Copyright © 2021, ABC Audio. All rights reserved.

Scoreboard roundup — 9/16/21

iStock

(NEW YORK) — Here are the scores from Thursday’s sports events:

MAJOR LEAGUE BASEBALL

AMERICAN LEAGUE
LA Angels 9, Chi White Sox 3
Oakland 7, Kansas City 2
Baltimore 3, NY Yankees 2
Tampa Bay 5, Detroit 2
Houston 12, Texas 1

NATIONAL LEAGUE
Cincinnati 1, Pittsburgh 0
San Diego 7, San Francisco 4
Philadelphia 17, Chi Cubs 8
Colorado at Atlanta (Postponed)

NATIONAL FOOTBALL LEAGUE
Washington 30, NY Giants 29

WOMEN’S NATIONAL BASKETBALL ASSOCIATION
Los Angeles 74, Atlanta 68

Copyright © 2021, ABC Audio. All rights reserved.

“Damn Strait,” Scotty McCreery’s driving the ‘Same Truck’ from ‘Idol’ — and delivering an important message

Jeff Ray

More than ten years after winning the tenth season of American IdolScotty McCreery arrives with his fifth studio album, driving the Same Truck he won on the popular singing competition. 

The 27-year-old wrote ten of the record’s twelve tracks, including his top five hit, “You Time.” In fact, he believed he was almost done with the follow-up to 2018’s Seasons Change — and then 2020 happened.

“You know, I thought I had this album pretty much ready to go a couple of years ago,” Scotty reveals. “But then after COVID hit, suddenly [I] had a lot of extra time on my hands. So I started writing new songs and before I knew it, we’d come up with almost a whole new album.”

For Scotty, Same Truck has both a literal and a much deeper meaning.

“Can you believe I’m actually driving the same truck I won 10 years ago as part of my American Idol title?” he asks. “The truck’s name is Loretta after one of my favorites, Loretta Lynn.”

Amid divisive times, Scotty believes we’re more alike than different, i.e. we’re all in the same boat — or “Same Truck,” if you’re from North Carolina. 

“[It] was one of those songs that got started by a conversation talking about how I drive the same truck…” he tells ABC Audio. “But it morphed into something a lot more important than that, just talking about how, ‘Hey, guys, we’re all on the same team here. Let’s build each other up instead of tear each other down.'”

“And it’s just a message I think we all need to hear right now,” he adds.  

Same Truck is new today, and features Scotty’s nod to King George“Damn Strait,” which he’s set to sing Tuesday on NBC’s Today show. 

Copyright © 2021, ABC Audio. All rights reserved.

Jennifer Aniston says season 2 of The Morning Show will tackle cancel culture

Courtesy of Apple TV+

After season one of The Morning Show ended on an incredible cliffhanger — with Alex Levy and Bradley Jackson choosing to blow up their network and expose the toxic work environment live on television — fans will finally know what happened next when season two premieres today on Apple TV+.

Star Jennifer Aniston, who plays Alex, chatted with ABC Audio about what themes the new season will tackle and how they will affect her character’s growth.

Aniston says that Alex — who spent much of the first season trying to process the sexual assault allegations against her disgraced former co-host, Steve Carell‘s Mitch Kessler — will do some real soul searching this season.

“Sitting back, taking a moment to look inward and look back at the rubble that was left behind and figuring out who you are, is it who you want to be, and how do you move forward in this new normal?,” she divulged.

The Emmy winner says Alex will continue to explore the fallout of the sex scandal and also focus on cancel culture.

“What happens to these people who, you know, commit these terrible acts? Do they just vanish and disappear? That’s it. One click and one swipe in your whole entire life that you worked for is over,” she explained. “Is there room for redemption? Is there room for forgiveness?”

While fans have yet to find that out, they will meet newcomer Julianna Margulies, who plays network news anchor Laura Peterson.

Margulies tells ABC Audio that Laura’s character is a mix of Diane SawyerRachel Maddow and Christiane Amanpour.

“There’s this sort of really great mix of grit, but sophistication and incredible smarts,” she teased. 

The Morning Show‘s first episode of season two is streaming now on Apple TV+. 

Copyright © 2021, ABC Audio. All rights reserved.

Billie Eilish loves that she “finally” got to do *this* in her Disney+ special

Jesse Grant/Getty Images for Disney

Billie Eilish‘s Disney+ special, Happier Than Ever: A Love Letter to Los Angeles, is currently streaming, and for Billie, one of the highlights of the project was the fact that she got to perform all the songs from her current album in order — something she says she considers “vitally important.”

“I’ve really always wanted to do a performance piece of a project of mine in order, just because that’s I feel that that’s how albums are supposed to be made and supposed to be listened to,” she tells ABC News. “For my first album and my first EP and this album, it’s always been important to me to make a very, you know, track-by-track album — like, a whole piece.”

She adds, “I always say that it’s, like, vitally important to listen to albums in order, all the way through.”

However, Billie admits that she’s been frustrated in the past by her inability to play her albums front to back in concert.

“Doing a live show, like, a real show for [a] tour or a festival or whatever, you can’t really do that because you have to play the old catalog,” notes Billie. “And you have to have…a kind of range and variety and dynamics and stuff. So it can’t always really be in order.”

“And that, from the beginning of me doing shows, always bothered me, ’cause I wanted it all to be in order,” she declares. “I got to finally do that. And, you know, who knows if I’ll do it again?”

Fans will have to wait until Billie’s Happier Than Ever tour kicks off in February 2022 to see if she’ll try to perform the album in its entirety again. In the meantime, there’s always the Disney+ special.

Disney is the parent company of ABC Audio.

Copyright © 2021, ABC Audio. All rights reserved.

Nas reveals he battled COVID-19

iStock/Lubo Ivanko

Nas celebrated his 48th birthday on September 14, and he says he’s grateful to be healthy now after contracting COVID-19 in October 2020.

“This is the first time [I’m] mentioning it,” he tells Ebony. “It was mentally and physically hard. It’s just today’s world, with chemical warfare, crazy politics, racism, food shortages, police malpractice, Black-on-Black murder. The human spirit is being tested.”

The rap icon is appreciating life more now. For his new “Brunch on Sunday” video, he dined with Los Angeles Lakers basketball stars LeBron James and Russell Westbrook, and Swizz Beatz, as well as his 27-year-old daughter, Destiny. They appear in all-white in the clip shot on the rooftop of the luxurious Catch restaurant in L.A.

Meanwhile, with a series of lucrative investments, including Coinbase cryptocurrency, Nasir has become known for his financial success.

“I got people that stop me in the street to ask me about investment tips more than music,” he reveals. “I met another Black man named Nasir; he’s doing his thing. He told me how I’m inspirational to him in that world of investors and fundraising.”

The Illmatic rapper, who dropped out of school in the eighth grade, is now focused on providing funding to assist others.

“Hip hop has created more Black millionaires than any other industry in America,” Nas comments. “Being able to invest in start-ups and invest in people’s futures…that’s what America is all about.”

As he looks back at his 30-year legacy, Nas hopes to be as highly regarded as his idols.

“I just wanna become as great as the ones I came up thinking were the greats,” he says. “Big Daddy Kane, Kool G Rap, LL [Cool J], Slick Rick, Ice Cube — the list goes on.”

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

A post shared by Nasir Jones (@nas)

Copyright © 2021, ABC Audio. All rights reserved.

Zakk Wylde reflects on 30th anniversary of Ozzy Osbourne’s ‘No More Tears’: “Just hilarious, man”

Sony

There may have been No More Tears on Ozzy Osbourne‘s 1991 solo album of the same name, but, according to Zakk Wylde, there were plenty of “shenanigans.”

Speaking with ABC Audio, Wylde recalls having a “blast” recording the quadruple-platinum record, which turns 30 today.

“The whole thing, recording it and drinking and the whole shenanigans that went on making that record were just hilarious, man,” Wylde shares.

No More Tears marked Osbourne’s second solo studio effort featuring the future Black Label Society frontman on guitar, following 1988’s No Rest for the Wicked. For round two, Wylde remembers feeling much more “relaxed.”

“The first album was, like, [a] ‘let’s see what you got’ kinda thing,” Wylde explains.

Wylde also felt more comfortable to explore some of his own personal influences on No More Tears, bringing in some of the Southern-rock twang from artists like The Allman Brothers Band and Lynyrd Skynyrd. You can definitely hear that in the intro for the single “Mama, I’m Coming Home,” which would become Ozzy’s biggest solo hit.

“Originally, me and Ozz had did it on a piano at my apartment at the time in North Hollywood,” Wylde says of “Mama.” “Ozz was over there, and then he had that melody…and he was singing that, and we ended up doing it on the piano. Then when we got in the studio is when I transposed it to guitar and put it on a 12-string.”

He adds, “When the album was done, when we listened to ‘Mama, I’m Coming Home,’ I was, like, ‘Man, this came out really good.'”

A 30th anniversary reissue of No More Tears is out today.

Wylde, meanwhile, is releasing a new Black Label Society album, Doom Crew Inc., on November 26.

Copyright © 2021, ABC Audio. All rights reserved.

20 years of ‘Room for Squares’: The slow and steady rise of John Mayer

Sony Legacy

Twenty years ago on this Saturday, John Mayer‘s major-label debut, Room for Squares, was released.  No overnight success, the album steadily climbed the charts until it finally reached the top 10 in 2002.  Here are Five Fascinating Facts about Room for Squares:

5. The album’s title is a play on the title of a 1963 album by jazz saxophonist Hank Mobley called No Room for Squares.

4. The original version of the album was released online in June of 2001, but after John landed a record deal with Columbia, the label remixed and re-released it with new artwork, an extra track called “3X5,” and four reworked songs from John’s 1999 indie EP Inside Wants Out.

3. John co-wrote several songs on Room for Squares, including “No Such Thing,” with his former college buddy Clay Cook, who’s now a member of the superstar country group Zac Brown Band.

2. By the end of 2002, Room for Squares had spun off the hits “No Such Thing,” “Your Body Is a Wonderland” and “Why Georgia.” In 2003, John won his first Grammy for “Your Body Is a Wonderland.”

1. In 2006, John allowed the TV show The Office to use “Your Body Is a Wonderland,” in exchange for a “Dundie” — a fictitious award given out by Steve Carell‘s character — for “Tallest Music Dude.”

20 years on, John Mayer still matters. He just won an MTV VMA last Sunday, and his current album, Sob Rock, released in July, became his 10th top 10 album.

Copyright © 2021, ABC Audio. All rights reserved.